Main features and benefits
Clinically relevant - recapitulates human ITP via Fcγ receptor-mediated phagocytosis and autoantibody-mediated platelet destruction.
Quantifiable endpoint - Platelet count (PLT) measurement by automated hematology analyzer or flow cytometry.
Flexible and Adjustable —Establish acute or chronic ITP models with single or repeated antibody administration; dose escalation for long-term thrombocytopenia.
Multiple strains - CD1 (outbred) and C57BL/6 (inbred) models to meet different experimental needs.
Translational Value – Ideal for testing thrombopoietin receptor agonists (eltrombopag, romiplostim), Fc blockers (fostamatinib), and immunomodulators (IVIG, anti-CD20).
IND Ready Packet – Research can be conducted in accordance with GLP principles.
Technical data and verification
2OA-BSA induced C57BL/6 mouse PBC model
Application areas
• Efficacy testing of thrombopoietin receptor agonists (eltrombopag, romiplostim, avatrombopag)
• Evaluation of Fc blockers (fostamatinib, efgartigimod) and complement inhibitors
• Testing of immunomodulators (IVIG, anti-CD20, anti-CD40L) and spleen tyrosine kinase (Syk) inhibitors
• Target validation of platelet clearance and autoimmune pathways
• Pharmacology and toxicology studies to support IND
Model specifications
| scope | CD1 mouse ITP model | C57BL/6 mouse ITP model |
| Species/Strain | CD1 mice (inbred strain) | C57BL/6 mice (inbred strain) |
| induction method | Intravenous anti-CD41 monoclonal antibody (eg, MWReg30, 0.5-10 μg/g)—single dose for acute ITP, repeated dose for chronic ITP |
| study time | Acute: 1-7 days; Chronic: 2-4 weeks (repeated doses) | Acute: 1-7 days; Chronic: 2-4 weeks (repeated doses) |
| critical endpoint | Platelet count (PLT), bleeding time, survival rate by hematology analyzer, optional: spleen histopathology, macrophage phenotyping |
| positive control | IVIG (intravenous immunoglobulin) or eltrombopag may be used as reference compounds |
| packet | Raw data, analysis reports, hematology results, bioinformatics (optional) |
❓ FAQ
Q: How do anti-CD41 antibodies induce thrombocytopenia?
Answer: Anti-CD41 antibody binds to platelet surface glycoprotein IIb (integrin αIIb) and regulates platelets. Fcγ receptors on splenic macrophages recognize antibody-coated platelets, resulting in Fc-mediated phagocytosis and rapid clearance from circulation, mimicking human ITP pathogenesis.
Q: What is the difference between CD1 and C57BL/6 ITP models?
A: CD1 mice are inbred, providing greater genetic diversity that can be used to model patient variability. C57BL/6 is an inbred strain with consistency and compatibility with transgenic and knockout strains, making it ideal for mechanistic studies.
Q: Can this model be used for IND support studies?
Answer: Yes. Studies can be conducted according to GLP principles for regulatory submissions (FDA, EMA).
Q: Do you offer customized study protocols (e.g., different antibody doses, single vs. repeated dosing, preventive vs. therapeutic treatment)?
Answer: Of course. Our scientific team customizes the anti-CD41 antibody dosage, dosing regimen (acute or chronic), and treatment duration based on your specific drug candidate.
Q: What is the typical timeline for a pilot efficacy study?
A: Acute ITP studies are usually completed within 7 days of antibody administration. Chronic ITP studies may last 2-4 weeks with repeated dosing and multiple platelet count assessments.
